Incannex Healthcare Limited (IXHL)

AU — Healthcare Sector
Peers: DLTNF  RAMMF  CVGRF  BHHKF  SPBBF  EGRX  ANIP  PAHC  DCPH  PBH  COLL  SSIC  RGC  PROC  SHPHF 

Automate Your Wheel Strategy on IXHL

With Tiblio's Option Bot, you can configure your own wheel strategy including IXHL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IXHL
  • Rev/Share 0.0014
  • Book/Share 0.0548
  • PB 4.5148
  • Debt/Equity 4.2456
  • CurrentRatio 1.7986
  • ROIC -2.1111

 

  • MktCap 17987211.0
  • FreeCF/Share -0.4474
  • PFCF -2.2809
  • PE -0.3526
  • Debt/Assets 0.3689
  • DivYield 0
  • ROE -2.0284

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
IXHL
Published: March 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase 3 study. Funds to support the advancement of Incannex's IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase 3 study.

Read More
image for news Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025
IXHL
Published: February 18, 2025 by: Newsfile Corp
Sentiment: Neutral

Dallas, Texas--(Newsfile Corp. - February 18, 2025) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonegate Capital Partners updates their coverage on Incannex Healthcare Inc. (NASDAQ: IXHL). During the second quarter of fiscal year 2025, Incannex Healthcare Inc. reported R&D costs of $1.4M, a decrease from $2.6M in the same period of the previous year.

Read More
image for news Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
IXHL
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK and MELBOURNE, Australia, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended December 31, 2024.

Read More
image for news Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

About Incannex Healthcare Limited (IXHL)

  • IPO Date 2022-03-02
  • Website https://www.incannex.com.au
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Mr. Joel Bradley Latham
  • Employees 9
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.